PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Abstract Background The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk meta...

Full description

Bibliographic Details
Main Authors: Hannah L. Buckley, Fiona J. Collinson, Gemma Ainsworth, Heather Poad, Louise Flanagan, Eszter Katona, Helen C. Howard, Geraldine Murden, Rosamonde E. Banks, Joanne Brown, Galina Velikova, Tom Waddell, Kate Fife, Paul D. Nathan, James Larkin, Thomas Powles, Sarah R. Brown, Naveen S. Vasudev
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Renal cancer
Nivolumab
Ipilimumab
Schedule
Safety
Efficacy
Online Access:http://link.springer.com/article/10.1186/s12885-019-6273-1

Similar Items

Similar Items